Crescent Biopharma Advances Clinical Trials
Enrollment is progressing in the global ASCEND Phase 1/2 trial of CR-001 and the company extended its cash runway into 2028.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day